Titlebook: New Therapeutic Targets in Rheumatoid Arthritis; Paul-Peter Tak Book 2009 Birkhäuser Basel 2009 Arthritis.Chemokine.Drug Target.Interleuki

FANG

B cell targets in rheumatoid arthritis,atients with RA using the first licensed agent, rituximab. Recent research has focused on enhancing efficacy using other targets to inhibit B cell function, including other B cell-depleting antibodies and cytokines critical to B cell function. The rationale for new B cell targets is discussed, as well as clinical data.

易弯曲

撤退

dithiolethione

邪恶的你

New Therapeutic Targets in Rheumatoid Arthritis978-3-7643-8238-4Series ISSN 1422-7746 Series E-ISSN 2296-4525

Irritate

Paul-Peter TakFocuses on therapeutic targets that have recently been registered or are currently under development..Each chapter discusses the biological rationale in great detail including results from clinical tr

言外之意

Role of IL-1 in erosive arthritis, lessons from animal models,e therapeutic target, in addition to TNF and IL-6. However, IL-1 dependency can be lost under conditions of T cell IL-17 abundance as well as the presence of Toll-like receptor ligands. The latter may underlie the variable responsiveness of rheumatoid arthritis patients to anti-cytokine therapy and warrants combination therapy for optimal control.

Fantasy

僵硬

peritonitis

IL-17 and Th17 cells, key players in arthritis, results previously obtained following the identification of IL-17 as a T cell-derived cytokine. At the same time, additional information was obtained on the other members of the IL-17 family and on the structure of the IL-17 receptor complex. Such knowledge has further extended the choice of possible modalities to control IL-17.